Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01305512 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetic, Safety and Tolerability Study of SPARC1028

A Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target

NCT01305512: Completed Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.

NCT01305512 is a Phase 1 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01305512, a Phase 1 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target

Study Summary

Evaluation of pharmacokinetic profile of SPARC1028

Primary Outcome

MTD for SPARC1028 will be determined as dose below the dose at which DLT (Dose Limiting Toxicity) is seen for ≥ 2 subjects

Interventions

  • DRUG SPARC1028

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2012-05
Est. Completion 2016-08
Phase Phase 1

What the finished NCT01305512 record still lists

NCT01305512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).

The record links to 0 conditions, and to 1 intervention - of which SPARC1028 is the first listed.

NCT01305512 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01305512 about?

NCT01305512 is a clinical study titled "Pharmacokinetic, Safety and Tolerability Study of SPARC1028". Evaluation of pharmacokinetic profile of SPARC1028

What is the current status of trial NCT01305512?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-05. Estimated completion is 2016-08.

What interventions are being tested in trial NCT01305512?

The interventions under investigation include: SPARC1028 (DRUG).

Who is sponsoring clinical trial NCT01305512?

This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01305512's enrollment target sits among peer trials

36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01305512, the US trial registry maintained by the National Library of Medicine. NCT01305512 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.